Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives

References

• CreagerMALuscherTFCosentinoFBeckmanJADiabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part ICirculation2003108121527153214504252
   PubMed Web of Science ®Google Scholar
• SheetzMJKingGLMolecular understanding of hyperglycemia’s adverse effects for diabetic complicationsJAMA2002288202579258812444865
   PubMed Web of Science ®Google Scholar
• GrillVBjorklundAOverstimulation and beta-cell functionDiabetes200150Suppl 1S122S12411272169
   PubMed Web of Science ®Google Scholar
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research GroupN Engl J Med1993329149779868366922
   PubMed Web of Science ®Google Scholar
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) GroupLancet199835291318378539742976
   PubMed Web of Science ®Google Scholar
• TurnerRCCullCAFrighiVHolmanRRGlycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) GroupJAMA1999281212005201210359389
   PubMed Web of Science ®Google Scholar
• KeatingGMExenatideDrugs2005651216811692 discussion 1693–1685.16060703
   PubMed Web of Science ®Google Scholar
• DruckerDJEnhancing incretin action for the treatment of type 2 diabetesDiabetes Care200326102929294014514604
   PubMed Web of Science ®Google Scholar
• JoySVRodgersPTScatesACIncretin mimetics as emerging treatments for type 2 diabetesAnn Pharmacother200539111011815562141
   PubMed Web of Science ®Google Scholar
• HolstJJThe physiology and pharmacology of incretins in type 2 diabetes mellitusDiabetes Obes Metab200810Suppl 3142118577153
   PubMed Web of Science ®Google Scholar
• WhitlockGLewingtonSSherlikerPBody-mass index and cause-specific mortality in 900,000 adults: collaborative analyses of 57 prospective studiesLancet282009373966910831096
   Google Scholar
• AmielSADixonTMannRJamesonKHypoglycaemia in Type 2 diabetesDiabet Med200825324525418215172
   PubMed Web of Science ®Google Scholar
• DavisSAlonsoMDHypoglycemia as a barrier to glycemic controlJ Diabetes Complications2004181606815019602
   PubMed Web of Science ®Google Scholar
• GreenJFeinglosMUpdate on type 2 diabetes mellitus: understanding changes in the diabetes treatment paradigmInt J Clin Pract Suppl200715431117593272
   PubMedGoogle Scholar
• KnudsenLBNielsenPFHuusfeldtPOPotent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administrationJ Med Chem20004391664166910794683
   PubMed Web of Science ®Google Scholar
• GonzalezCBerutoVKellerGSantoroSDi GirolamoGInvestigational treatments for Type 2 diabetes mellitus: exenatide and liraglutideExpert Opin Investig Drugs2006158887895
   PubMed Web of Science ®Google Scholar
• AgersoHJensenLBElbrondBRolanPZdravkovicMThe pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy menDiabetologia200245219520211935150
   PubMed Web of Science ®Google Scholar
• KreymannBWilliamsGGhateiMABloomSRGlucagonlike peptide-1 7–36: a physiological incretin in manLancet198728571130013042890903
   PubMed Web of Science ®Google Scholar
• WettergrenASchjoldagerBMortensenPEMyhreJChristiansenJHolstJJTruncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in manDig Dis Sci19933846656738462365
   PubMed Web of Science ®Google Scholar
• NaslundEGutniakMSkogarSRossnerSHellstromPMGlucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese menAm J Clin Nutr19986835255309734726
   PubMed Web of Science ®Google Scholar
• BregenholtSMoldrupABlumeNThe long-acting glucagonlike peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitroBiochem Biophys Res Commun2005330257758415796922
   PubMed Web of Science ®Google Scholar
• MariADegnKBrockBRungbyJFerranniniESchmitzOEffects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditionsDiabetes Care20073082032203317468345
   PubMed Web of Science ®Google Scholar
• SeinoYRasmussenMFZdravkovicMKakuKDose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetesDiabetes Res Clin Pract200881216116818495285
   PubMed Web of Science ®Google Scholar
• JuhlCBHollingdalMSturisJBedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetesDiabetes200251242442911812750
   PubMed Web of Science ®Google Scholar
• MadsbadSSchmitzORanstamJJakobsenGMatthewsDRImproved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trialDiabetes Care20042761335134215161785
   PubMed Web of Science ®Google Scholar
• MarreMShawJBrandleMLiraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)Diabet Med200926326827819317822
   PubMed Web of Science ®Google Scholar
• NauckMFridAHermansenKEfficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 studyDiabetes Care2009321849018931095
   PubMed Web of Science ®Google Scholar
• GarberAHenryRRatnerRLiraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trialLancet2009373966247348118819705
   PubMed Web of Science ®Google Scholar
• ZinmanBGerichJBuseJBEfficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD)Diabetes Care20093271224123019289857
   PubMed Web of Science ®Google Scholar
• Russell-JonesDVaagASchmitzOLiraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trialDiabetologia200952102046205519688338
   PubMed Web of Science ®Google Scholar
• BuseJBRosenstockJSestiGLiraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)Lancet20093749683394719515413
   PubMed Web of Science ®Google Scholar
• AstrupARossnerSVan GaalLEffects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled studyLancet200937497011606161619853906
   PubMed Web of Science ®Google Scholar
• LiuHDearAEKnudsenLBSimpsonRWA long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion moleculesJ Endocrinol20092011596619136619
   PubMed Web of Science ®Google Scholar
• NoelRABraunDKPattersonREBloomgrenGLIncreased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort studyDiabetes Care200932583483819208917
   PubMed Web of Science ®Google Scholar
• BainSCStephensJWExenatide and pancreatitis: an updateExpert Opin Drug Saf20087664364418983211
   PubMed Web of Science ®Google Scholar
• StephensJWBainSCSafety and adverse effects associated with GLP-1 analoguesExpert Opin Drug Saf20076441742217688385
   PubMed Web of Science ®Google Scholar
• KendallDMRiddleMCRosenstockJEffects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylureaDiabetes Care20052851083109115855571
   PubMed Web of Science ®Google Scholar
• HeineRJVan GaalLFJohnsDMihmMJWidelMHBrodowsRGExenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trialAnn Intern Med2005143855956916230722
   PubMed Web of Science ®Google Scholar
• de HeerJHolstJJSulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1Diabetes200756243844317259389
   PubMed Web of Science ®Google Scholar
• HaunerHStockampBHaastertBPrevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factorsExp Clin Endocrinol Diabetes199610421061108740933
   PubMed Web of Science ®Google Scholar
• RuvalcabaRHKletterGBAbdominal lipohypertrophy caused by injections of growth hormone: a case reportPediatrics19981022 Pt 14084109714655
   PubMed Web of Science ®Google Scholar
• FeinglosMNSaadMFPi-SunyerFXAnBSantiagoOEffects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetesDiabet Med20052281016102316026367
   PubMed Web of Science ®Google Scholar
• FridANMHermansenKKolotkinRLHammerMZdravkovicMMatthewsDEvaluation of patient reported outcomes in subjects with type 2 diabetes treated with the once-daily human GLP-1 analog liraglutide or glimepiride, both as add-on to metforminAmerican Diabetes Association’s 68th Scientific SessionsJune 2008 Abstract 2080-PO.
   Google Scholar
• SchmidtWECJHammerMZychmaMBuseJBPatient-reported outcoes are superior in patients with type 2 diabetes treated with liraglutide as compared to exenatide, when added to metformin, sulfonylurea or both (LEAD-6)American Diabetes Association’s 69th Scientific SessionsJune 2009Abstract P-1880.
   Google Scholar